Module 6.2 - Digoxin and Cardioactive Steroid Toxicology - Podcast

Welcome to the Creative Commons Rx Podcast!

Before diving into this episode, I want to ensure we're all on the same page.

This is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient or pharmacist-patient relationship is formed. Using this information and the materials linked to this podcast is at the user's risk. The content on this podcast is not intended to substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice from any medical condition they have, and they should seek the assistance of their health care professionals for any such conditions.

Clinical experts created the references, content, and clinical insight. NotebookLM, a Google AI tool, created the audio content, which I extensively reviewed before release.

Finally, the host states that he takes all conflicts of interest seriously. Currently, there are no conflicts to disclose. For all of his disclosures and the companies he invests in or advises, he directs users to reach out independently, where he keeps an up-to-date and active list of all disclosures.




This comprehensive review offers a deep dive into digoxin toxicology, a crucial topic given this cardioactive steroid’s narrow therapeutic index. We begin by examining the pharmacology of digoxin, which reversibly inhibits the Na+K+-ATPase pump. This leads to increased intracellular sodium, reversing the sodium-calcium exchanger (NCX) and increasing intracellular calcium, ultimately causing positive inotropy (enhanced contractility) and negative chronotropy (slower heart rate).
Patient safety hinges on identifying predisposing factors for toxicity, including advanced age, underlying cardiac disease, renal insufficiency (as digoxin is primarily renally excreted), and key electrolyte disturbances such as hypokalemia, hypomagnesemia, and hypercalcemia.
A major focus is distinguishing between acute and chronic toxicity:
Acute poisoning often results from a single large dose, where hyperkalemia is a strong predictor of poor outcomes and indicates the need for anti-digoxin Fab fragments.
Chronic toxicity is more common, developing gradually, especially in patients with renal failure. It frequently presents with non-specific gastrointestinal, neurological, or visual symptoms (like xanthopsia—seeing yellow halos), and is often associated with hypokalemia.
The mainstay of managing severe toxicity is the prompt administration of Digoxin-specific Fab fragments (DSFab), the primary antidote, indicated for life-threatening arrhythmias, hyperkalemia , or hemodynamic instability. We detail calculation methods for DSFab dosing, based on either ingested amount or serum concentration, while noting that empirical dosing is often necessary due to clinical uncertainties.
A vital clinical pearl for supportive care is the critical avoidance of calcium salts when managing hyperkalemia in this setting. Giving calcium can exacerbate toxicity by further increasing myocardial intracellular calcium overload, potentially leading to dangerous arrhythmias. Close monitoring and correction of electrolyte disturbances (especially hypokalemia) are essential before and after Fab fragment treatment. Sharpen your knowledge to ensure effective management of this complex cardioactive steroid!